Certain Common Stock of Agile Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-AUG-2022.
August 15, 2022
Share
Certain Common Stock of Agile Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-AUG-2022. These Common Stock will be under lockup for 46 days starting from 1-JUL-2022 to 16-AUG-2022.
Details:
The company and each of our officers and directors have agreed with the placement agent to be subject to a lock-up period of forty-five days following the date of this prospectus. This means that, during the applicable lock-up period, we may not offer for sale, contract to sell, or sell any shares of our common stock or any securities convertible into, or exercisable or exchangeable for, shares of our common stock subject to certain customary exception such as issuing stock options to directors, officers, employees and consultants under our existing plans.
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
AGILE THERAPEUTICS, INC. 
